New hope for leukemia patients: immunotherapy combo aims to boost survival
NCT ID NCT06860269
First seen Feb 16, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This study is for adults aged 18-65 newly diagnosed with acute lymphoblastic leukemia (ALL). It tests adding newer immunotherapy drugs (blinatumomab for B-cell ALL, isatuximab for T-cell ALL) to standard treatment, and refines when a stem cell transplant is needed. The goal is to improve survival and reduce relapse. About 1,200 participants will be enrolled across multiple countries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.